Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 4.87
NRCIB's Cash to Debt is ranked higher than
72% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. NRCIB: 4.87 )
NRCIB' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: 4.87

Equity to Asset 0.68
NRCIB's Equity to Asset is ranked higher than
77% of the 285 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. NRCIB: 0.68 )
NRCIB' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.8
Current: 0.68

0.34
0.8
Interest Coverage 92.77
NRCIB's Interest Coverage is ranked higher than
65% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 261.43 vs. NRCIB: 92.77 )
NRCIB' s 10-Year Interest Coverage Range
Min: 5.98   Max: 9999.99
Current: 92.77

5.98
9999.99
F-Score: 7
Z-Score: 8.26
M-Score: -3.00
WACC vs ROIC
8.50%
31.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 28.63
NRCIB's Operating margin (%) is ranked higher than
98% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.79 vs. NRCIB: 28.63 )
NRCIB' s 10-Year Operating margin (%) Range
Min: 11.54   Max: 32.96
Current: 28.63

11.54
32.96
Net-margin (%) 18.37
NRCIB's Net-margin (%) is ranked higher than
97% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.93 vs. NRCIB: 18.37 )
NRCIB' s 10-Year Net-margin (%) Range
Min: 2.82   Max: 34.17
Current: 18.37

2.82
34.17
ROE (%) 22.40
NRCIB's ROE (%) is ranked higher than
96% of the 273 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. NRCIB: 22.40 )
NRCIB' s 10-Year ROE (%) Range
Min: 2.82   Max: 117.05
Current: 22.4

2.82
117.05
ROA (%) 14.99
NRCIB's ROA (%) is ranked higher than
97% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. NRCIB: 14.99 )
NRCIB' s 10-Year ROA (%) Range
Min: 2.05   Max: 41.09
Current: 14.99

2.05
41.09
ROC (Joel Greenblatt) (%) 236.23
NRCIB's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.09 vs. NRCIB: 236.23 )
NRCIB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 20.77   Max: 2400
Current: 236.23

20.77
2400
Revenue Growth (3Y)(%) -43.40
NRCIB's Revenue Growth (3Y)(%) is ranked higher than
55% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. NRCIB: -43.40 )
NRCIB' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 19.7
Current: -43.4

0
19.7
EBITDA Growth (3Y)(%) -42.70
NRCIB's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. NRCIB: -42.70 )
NRCIB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 42
Current: -42.7

0
42
EPS Growth (3Y)(%) -39.70
NRCIB's EPS Growth (3Y)(%) is ranked higher than
57% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. NRCIB: -39.70 )
NRCIB' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 58.7
Current: -39.7

0
58.7
» NRCIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

NRCIB Guru Trades in Q1 2014

Chuck Royce 2,100 sh (New)
» More
Q2 2014

NRCIB Guru Trades in Q2 2014

Chuck Royce 2,100 sh (unchged)
» More
Q3 2014

NRCIB Guru Trades in Q3 2014

Chuck Royce 2,100 sh (unchged)
» More
Q4 2014

NRCIB Guru Trades in Q4 2014

Chuck Royce 1,780 sh (-15.24%)
» More
» Details

Insider Trades

Latest Guru Trades with NRCIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on National Research Corp

Meridian Funds Comments on National Research Corp - Jun 20, 2014

National Research Corp. (NRCIB) experienced strong gains during the two-week period ending December 31, 2013. The company provides performance measurement services to the healthcare industry to help providers and payers measure outcomes. We believe that National Research is well positioned for the evolving healthcare landscape and has a strong business model characterized by recurring revenues, high margins, and returns on equity in excess of 20%. Additionally, the A shares owned by the Fund closed the year at a 45.8% discount to the B shares; we expect this valuation discrepancy to narrow over time.



From Meridian Funds's semi-annual report ended December 31, 2013.



Check out Meridian Funds latest stock trades

Top Ranked Articles about National Research Corp

Meridian Funds Comments on National Research Corp
National Research Corp. (NRCIB) experienced strong gains during the two-week period ending December 31, 2013. The company provides performance measurement services to the healthcare industry to help providers and payers measure outcomes. We believe that National Research is well positioned for the evolving healthcare landscape and has a strong business model characterized by recurring revenues, high margins, and returns on equity in excess of 20%. Additionally, the A shares owned by the Fund closed the year at a 45.8% discount to the B shares; we expect this valuation discrepancy to narrow over time. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 48.10
NRCIB's P/E(ttm) is ranked higher than
78% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NRCIB: 48.10 )
NRCIB' s 10-Year P/E(ttm) Range
Min: 2.18   Max: 68.23
Current: 48.1

2.18
68.23
Forward P/E 37.04
NRCIB's Forward P/E is ranked higher than
83% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NRCIB: 37.04 )
N/A
PE(NRI) 43.40
NRCIB's PE(NRI) is ranked higher than
84% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NRCIB: 43.40 )
NRCIB' s 10-Year PE(NRI) Range
Min: 2.18   Max: 68.45
Current: 43.4

2.18
68.45
P/B 10.00
NRCIB's P/B is ranked lower than
56% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NRCIB: 10.00 )
NRCIB' s 10-Year P/B Range
Min: 0.4   Max: 16.26
Current: 10

0.4
16.26
P/S 8.84
NRCIB's P/S is ranked higher than
51% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.98 vs. NRCIB: 8.84 )
NRCIB' s 10-Year P/S Range
Min: 0.32   Max: 11.58
Current: 8.84

0.32
11.58
PFCF 37.00
NRCIB's PFCF is ranked higher than
80% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NRCIB: 37.00 )
NRCIB' s 10-Year PFCF Range
Min: 1.45   Max: 68.45
Current: 37

1.45
68.45
POCF 30.02
NRCIB's POCF is ranked higher than
81% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NRCIB: 30.02 )
NRCIB' s 10-Year POCF Range
Min: 1.23   Max: 58.94
Current: 30.02

1.23
58.94
EV-to-EBIT 12.99
NRCIB's EV-to-EBIT is ranked higher than
95% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NRCIB: 12.99 )
NRCIB' s 10-Year EV-to-EBIT Range
Min: -0.2   Max: 43.2
Current: 12.99

-0.2
43.2
Shiller P/E 17.90
NRCIB's Shiller P/E is ranked higher than
100% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NRCIB: 17.90 )
NRCIB' s 10-Year Shiller P/E Range
Min: 2.84   Max: 19.9
Current: 17.9

2.84
19.9
Current Ratio 1.90
NRCIB's Current Ratio is ranked higher than
62% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. NRCIB: 1.90 )
NRCIB' s 10-Year Current Ratio Range
Min: 0.49   Max: 5.21
Current: 1.9

0.49
5.21
Quick Ratio 1.90
NRCIB's Quick Ratio is ranked higher than
66% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. NRCIB: 1.90 )
NRCIB' s 10-Year Quick Ratio Range
Min: 0.49   Max: 5.21
Current: 1.9

0.49
5.21
Days Sales Outstanding 29.97
NRCIB's Days Sales Outstanding is ranked higher than
94% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.03 vs. NRCIB: 29.97 )
NRCIB' s 10-Year Days Sales Outstanding Range
Min: 29.97   Max: 82.49
Current: 29.97

29.97
82.49

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.03
NRCIB's Dividend Yield is ranked higher than
79% of the 89 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.35 vs. NRCIB: 2.03 )
NRCIB' s 10-Year Dividend Yield Range
Min: 0.94   Max: 23.2
Current: 2.03

0.94
23.2
Dividend Payout 0.49
NRCIB's Dividend Payout is ranked higher than
99% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NRCIB: 0.49 )
NRCIB' s 10-Year Dividend Payout Range
Min: 0.43   Max: 3.36
Current: 0.49

0.43
3.36
Dividend growth (3y) -41.10
NRCIB's Dividend growth (3y) is ranked higher than
63% of the 49 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. NRCIB: -41.10 )
NRCIB' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 20.5
Current: -41.1

0
20.5
Yield on cost (5-Year) 0.59
NRCIB's Yield on cost (5-Year) is ranked lower than
72% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. NRCIB: 0.59 )
NRCIB' s 10-Year Yield on cost (5-Year) Range
Min: 0.26   Max: 6.53
Current: 0.59

0.26
6.53
Share Buyback Rate -93.00
NRCIB's Share Buyback Rate is ranked lower than
52% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.70 vs. NRCIB: -93.00 )
NRCIB' s 10-Year Share Buyback Rate Range
Min: 0   Max: -94.1
Current: -93

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 197.20
NRCIB's Price/Net Current Asset Value is ranked higher than
65% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NRCIB: 197.20 )
NRCIB' s 10-Year Price/Net Current Asset Value Range
Min: 0.4   Max: 76.53
Current: 197.2

0.4
76.53
Price/Tangible Book 36.20
NRCIB's Price/Tangible Book is ranked higher than
51% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NRCIB: 36.20 )
NRCIB' s 10-Year Price/Tangible Book Range
Min: 0.2   Max: 3494
Current: 36.2

0.2
3494
Price/DCF (Projected) 3.90
NRCIB's Price/DCF (Projected) is ranked higher than
82% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NRCIB: 3.90 )
NRCIB' s 10-Year Price/DCF (Projected) Range
Min: 0.12   Max: 4.42
Current: 3.9

0.12
4.42
Price/Median PS Value 16.10
NRCIB's Price/Median PS Value is ranked higher than
52% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. NRCIB: 16.10 )
NRCIB' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 16.77
Current: 16.1

0.38
16.77
Price/Graham Number 8.80
NRCIB's Price/Graham Number is ranked higher than
80% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NRCIB: 8.80 )
NRCIB' s 10-Year Price/Graham Number Range
Min: 0.13   Max: 14.77
Current: 8.8

0.13
14.77
Earnings Yield (Greenblatt) 6.90
NRCIB's Earnings Yield (Greenblatt) is ranked higher than
93% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. NRCIB: 6.90 )
NRCIB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.3   Max: 2139.6
Current: 6.9

2.3
2139.6
Forward Rate of Return (Yacktman) -29.40
NRCIB's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.80 vs. NRCIB: -29.40 )
NRCIB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -30.6   Max: 65.8
Current: -29.4

-30.6
65.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:ADP, G, ENV, CMPGY, SGSOY » details
National Research Corp is a Wisconsin corporation, founded in 1981. The Company implements surveys and performs analysis that recognize a provider's strengths and problem areas, and then uses the data to design specific, measurable improvement strategies. The Company's portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company partners with clients across the continuum of healthcare services. The Company's clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The two operating segments, organized by geographic area, are National Research Corporation (United States) and National Research Corporation Canada, which each offer a portfolio of solutions to address specific market needs around growth, retention, engagement and thought leadership for healthcare organizations. The Company's primary competitors among such specialty firms include Press Ganey. The Company competes with traditional market research firms which are significant providers of survey-based, general market research and firms which provide services or products that complement healthcare performance assessments such as healthcare software or information systems.
» More Articles for NRCIB

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on National Research Corp Jun 20 2014 
My 4 Favorite Stocks From The Undervalued Predictable Screener Oct 11 2013 
Four Predictable, Undervalued Stocks Held by Billionaire Investors Sep 22 2013 
13 Not Expensive Stocks with Dividend Yields Over 3% as Well as a Consistent Business Sep 10 2013 
4 Really Undervalued Stocks With High Quality Dividends And A Consistent Business Sep 02 2013 

More From Other Websites
Nasdaq stocks posting largest volume increases Apr 24 2015
Report: Georgia Nursing Homes Exceed National Satisfaction Rates Apr 24 2015
REPORT: GEORGIA NURSING HOMES EXCEED NATIONAL SATISFACTION RATES Apr 24 2015
Nielsen Holdings (NLSN) Misses Q1 Earnings and Revenues - Analyst Blog Apr 22 2015
NATIONAL RESEARCH CORPORATION AND VISITING NURSE ASSOCIATIONS OF AMERICA TO ENCOURAGE VNAA MEMBERS... Apr 20 2015
National Research Corporation and Visiting Nurse Associations of America to encourage VNAA members... Apr 20 2015
Alabama Nursing Homes Continue to Exceed National Satisfaction Rates; Alabama Nursing Home... Apr 16 2015
Alabama Nursing Homes Continue to Exceed National Satisfaction Rates; Alabama Nursing Home... Apr 16 2015
National Research Reaches 25,000-Physician Milestone with Healthcare Transparency Solution Apr 09 2015
National Research Reaches 25,000-Physician Milestone with Healthcare Transparency Solution Apr 09 2015
National Research Corporation Declares Quarterly Dividend Mar 09 2015
GOVERNANCE TRAINING PROGRAM IN QUALITY AND SAFETY COMING SOON Mar 09 2015
10-K for National Research Corp. Mar 06 2015
Nielsen Holdings (NLSN) Prices 8 Million Secondary Offering - Analyst Blog Mar 03 2015
Nielsen's Subsidiaries Set $750M Senior Notes Price Tag - Analyst Blog Feb 23 2015
BayCare HomeCare Named to 2014 HomeCare Elite Feb 18 2015
Nielsen Holdings (NLSN) Beats Q4 Earnings; Lags Revenues - Analyst Blog Feb 12 2015
National Research posts 4Q profit Feb 10 2015
National Research posts 4Q profit Feb 10 2015
National Research Corporation Announces Fourth Quarter and Year-End 2014 Results Feb 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK